AIDOT Co., Ltd. announced on April 16 that it has received US Patent Office registration for its AI-based ‘Automatic Cervical Cancer Diagnostic System’. This patent covers an AI-based system that automatically diagnoses cervical cancer by classifying cervical data according to precise criteria for machine learning, and then diagnosing cervical cancer based on this machine learning. After completing domestic (Korean) patent registration in 2021, AIDOT has also registered this patent in Japan, China, and Indonesia, and has filed applications in other major markets as well. This US patent registration is seen as both securing AIDOT’s technological lead in the US market and recognition of its global technological capabilities. The scope of protection of this patent is particularly broad, making it highly effective in safeguarding the technology and raising barriers to entry for latecomers. AIDOT CEO Jaehoon Jung stated, “We have already confirmed that Cerviray can be used for insurance claims in the US through FDA 510K approval and CPT application, and this newly registered US patent—our second after the ‘Cervical Image Acquisition Apparatus’ registered in January—further strengthens Cerviray’s competiveness in the US market.” He added, “With this, AI medical devices developed in Korea have been recognized for commercial viability and practical value in the US market. We have also reached an agreement to achieve tangible results through close partnership with our US partners.” 

Korea Economic TV / 2024.04.23 / Deputy Director Yang Jae-jun